NetraMark Signs New Contract To Analyze Phase 2 Neurodegeneration Trial Data With Contract Research Organization Partner

About this update from Netramark Holdings Inc

TORONTO, July 09, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the "Company" or "NetraMark") (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a company developing advanced artificial intelligence solutions for clinical trial optimization and precision medicine, today announced that it signed a new contract to analyze a phase 2 neurodegeneration dataset through its established contract research organization (CRO) partnership. "This contract is an important commercial milestone for NetraMark because it represents our first contract flowing through a CRO, rather than directly with a biopharmaceutical company," said George Achilleos, Chief Executive Officer of NetraMark. "We believe this reflects a meaningful expansion of how NetraAI can reach biopharmaceutical companies, by becoming part of the broader clinical development infrastructure that CROs use to support sponsors." The agreement will allow NetraMark to analyze the phase 2 clinical trial data to support future development and clinical trial planning for neurodegenerative disorders. Neurodegenerative disorders represent one of the most challenging areas of clinical development due to disease heterogeneity, progression rates, and the difficulty of identifying patients most likely to respond to treatment. Advanced analytical approaches that can identify clinically meaningful patient subgroups may provide valuable insights for future development strategies. The partnership combines the CRO's global clinical development expertise with NetraMark's explainable AI platform and experienced industry team to analyze a neurodegenerative disease dataset. Under this agreement, NetraMark will apply its proprietary NetraAI platform to evaluate available trial data with the objective of identifying explainable Model-Derived Subgroups (MDS) and treatment-response patterns that may not be apparent through conventional analytical approaches. The analyses are intended to generate clinically interpretable insights that may support patient stratification, better trial design, and future drug-development decisions. This engagement further extends NetraMark's growing portfolio of AI-driven projects in central nervous system (CNS) disorders and reflects increasing interest in explainable AI approaches that may generate and deliver actionable insights from complex clinical datasets.

View stock analysis, news, and events for Netramark Holdings Inc